Logo Logo Logo
  • Company


    • Company Overview


    • Board of Directors


    • Executive Team


    • Advisory Board
  • Pipeline


    • Product Overview


    • AR-301 (Salvecin®)


    • AR-320 (Suvratoxumab)


    • AR-501 (Panaecin™)


    • AR-712 (COVID-19 mAb)


    • AR-701 (COVID-19 mAb)

    • Preclinical


      • AR-401

    • Out-licensed Products


      • AR-105 (Aerucin®)


      • AR-101 (Aerumab™)


      • AR-201
  • TECHNOLOGY


    • Technology Overview


    • APEXTM


    • MabIgX®


    • Therapeutic Targets


      • HAP / VAP


      • VAP Prevention


      • Cystic Fibrosis


      • COVID-19 Disease
  • Investors
    • Welcome
    • Corporate Governance
      • Board of Directors
      • Board Committees
    • News Releases
    • SEC Filings
    • Stock Information
      • Interactive Chart
      • Investment Calculator
      • Historical Stock Price
      • Analyst Coverage
    • Events and Webcasts
    • Publications and Posters
    • Investor alerts
    • Investor Inquiries
  • Contact Us


    • Contact Us


    • Careers
  • Company


    • Company Overview


    • Board of Directors


    • Executive Team


    • Advisory Board
  • Pipeline


    • Product Overview


    • AR-301 (Tosatoxumab)


    • AR-320 (Suvratoxumab)


    • AR-501 (Panaecin™)


    • AR-712 (COVID-19 mAb)


    • AR-701 (COVID-19 mAb)

    • Preclinical



      • AR-401

    • Out-licensed Products



      • AR-105 (Aerucin®)


      • AR-101 (AerumabTM)


      • AR-201
  • TECHNOLOGY


    • Overview


    • MabIgX®


    • Therapeutic Targets



      • HAP / VAP


      • VAP Prevention


      • Cystic Fibrosis


      • COVID-19 Disease
  • Investors
    • Welcome
    • Corporate Governance
      • Board of Directors
      • Board Committees
    • News Releases
    • SEC Filings
    • Stock Information
      • Interactive Chart
      • Investment Calculator
      • Historical Stock Price
      • Analyst Coverage
    • Events and Webcasts
    • Publications and Posters
    • Investor alerts
    • Investor Inquiries
  • Contact Us


    • Contact Us


    • Careers
Search:
 



Investors

Aridis Pharmaceuticals
YearTrailing 12-MonthsCalendar Year 2022Calendar Year 2021Calendar Year 2020Calendar Year 2019Calendar Year 2018Calendar Year 2016Calendar Year 2015Calendar Year 2014
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
FormDescriptionDateFormat
EFFECTNotice from the SEC of registration effectivenessSep 6, 2019Open Notice from the SEC of registration effectiveness in HTML.Open Notice from the SEC of registration effectiveness in DOC file.Open Notice from the SEC of registration effectiveness in PDF file.Open Notice from the SEC of registration effectiveness in XLS file.
DRSDRSAug 13, 2019Open DRS in HTML.Open DRS in DOC file.Open DRS in PDF file.Open DRS in XLS file.

CONTACT US

Aridis Pharmaceuticals Inc.
983 University Ave Suite B
Los Gatos, CA 95032
Phone: 408-385-1742
Fax: 408-960-3822

 

ADDITIONAL INFORMATION

Site Map
Privacy Policy
Financial Conflict of Interest Policy